Tiny play­er picks up $30M to go af­ter CAR-T's biggest chal­lenges

Of all the chal­lenges as­so­ci­at­ed with reengi­neer­ing CAR-T ther­a­pies — which have been wild­ly suc­cess­ful in treat­ing cer­tain blood can­cers — to at­tack sol­id tu­mors, tox­i­c­i­ty of­ten …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER